Protara Historical Balance Sheet

TARA Stock

USD 3.01 0.03 0.99%

Trend analysis of Protara Therapeutics balance sheet accounts such as Net Tangible Assets of 71.9 M, Property Plant And Equipment Net of 6.9 M, Accounts Payable of 2.6 M or Cash of 50.6 M provides information on Protara Therapeutics' total assets, liabilities, and equity, which is the actual value of Protara Therapeutics to its prevalent stockholders. By breaking down trends over time using Protara Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Protara Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Protara Therapeutics is a good buy for the upcoming year.

Protara Therapeutics Inventory

951,200

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.

About Protara Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Protara Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Protara Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Protara Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Protara currently owns. An asset can also be divided into two categories, current and non-current.

Protara Therapeutics Balance Sheet Chart

At present, Protara Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 2.3 M, whereas Total Current Liabilities is forecasted to decline to about 4.8 M.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Protara Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Protara Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Protara Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Protara Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Protara Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Protara Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.At present, Protara Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 2.3 M, whereas Total Current Liabilities is forecasted to decline to about 4.8 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	1.6M	2.3M	1.7M	2.3M
Total Assets	172.6M	113.3M	79.0M	92.2M

Other Current Liab Total Assets

Protara Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Retained Earnings Total Equity	Common Stock Shares Outstanding	Short Term Investments	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Other Assets
Total Assets		-0.26	0.0	1.0	0.93	0.45	-0.66	0.74	0.3	0.71	0.76	0.5	0.92	-0.51	0.81	0.55	0.4	0.45	0.05	0.23	0.32	0.44	0.92	-0.16	0.39	0.89
Other Current Liab	-0.26		0.83	-0.29	-0.36	-0.14	0.26	-0.26	-0.25	-0.27	-0.16	-0.12	-0.26	0.46	-0.33	-0.14	0.04	-0.14	0.13	0.17	0.39	-0.13	-0.26	0.47	-0.13	-0.12
Total Current Liabilities	0.0	0.83		-0.06	-0.01	0.39	0.32	-0.31	0.25	-0.29	0.15	0.33	-0.1	0.02	0.14	0.37	0.44	0.36	0.57	0.5	0.82	0.4	-0.09	0.21	0.4	0.01
Total Stockholder Equity	1.0	-0.29	-0.06		0.93	0.4	-0.69	0.77	0.27	0.74	0.73	0.47	0.93	-0.49	0.79	0.5	0.35	0.41	0.0	0.18	0.26	0.39	0.94	-0.15	0.34	0.89
Net Tangible Assets	0.93	-0.36	-0.01	0.93		0.45	-0.65	0.72	0.48	0.7	0.6	0.56	0.91	-0.55	0.91	0.54	0.39	0.5	0.22	0.15	0.32	0.46	0.92	-0.15	0.43	0.8
Property Plant And Equipment Net	0.45	-0.14	0.39	0.4	0.45		0.29	-0.16	0.69	-0.2	0.74	0.7	0.17	-0.71	0.69	0.94	0.79	0.8	0.64	0.71	0.82	1.0	0.18	-0.49	0.98	0.24
Net Debt	-0.66	0.26	0.32	-0.69	-0.65	0.29		-0.79	0.01	-0.99	-0.08	-0.19	-0.86	0.07	-0.39	0.07	0.36	0.03	0.36	0.26	0.34	0.28	-0.85	-0.11	0.29	-0.6
Retained Earnings	0.74	-0.26	-0.31	0.77	0.72	-0.16	-0.79		-0.16	0.77	0.33	-0.1	0.83	-0.02	0.44	-0.12	0.06	-0.17	-0.34	-0.38	-0.19	-0.18	0.83	0.24	-0.24	0.85
Accounts Payable	0.3	-0.25	0.25	0.27	0.48	0.69	0.01	-0.16		0.08	0.2	0.82	0.28	-0.52	0.77	0.74	0.42	0.61	0.62	0.36	0.48	0.74	0.29	-0.3	0.79	0.0
Cash	0.71	-0.27	-0.29	0.74	0.7	-0.2	-0.99	0.77	0.08		0.14	0.28	0.89	-0.14	0.47	0.02	-0.31	0.04	-0.31	-0.2	-0.28	-0.18	0.89	0.07	-0.19	0.61
Non Current Assets Total	0.76	-0.16	0.15	0.73	0.6	0.74	-0.08	0.33	0.2	0.14		0.46	0.44	-0.61	0.58	0.71	0.63	0.6	0.3	0.57	0.58	0.71	0.45	-0.37	0.65	0.63
Non Currrent Assets Other	0.5	-0.12	0.33	0.47	0.56	0.7	-0.19	-0.1	0.82	0.28	0.46		0.41	-0.69	0.72	0.86	0.26	0.82	0.59	0.68	0.55	0.74	0.42	-0.48	0.79	0.13
Cash And Short Term Investments	0.92	-0.26	-0.1	0.93	0.91	0.17	-0.86	0.83	0.28	0.89	0.44	0.41		-0.34	0.76	0.32	0.16	0.25	-0.12	-0.03	0.08	0.18	1.0	0.0	0.14	0.84
Common Stock Total Equity	-0.51	0.46	0.02	-0.49	-0.55	-0.71	0.07	-0.02	-0.52	-0.14	-0.61	-0.69	-0.34		-0.6	-0.74	-0.41	-0.82	-0.34	-0.62	-0.43	-0.7	-0.34	0.88	-0.7	-0.23
Retained Earnings Total Equity	0.81	-0.33	0.14	0.79	0.91	0.69	-0.39	0.44	0.77	0.47	0.58	0.72	0.76	-0.6		0.74	0.57	0.59	0.39	0.26	0.5	0.71	0.77	-0.22	0.69	0.61
Common Stock Shares Outstanding	0.55	-0.14	0.37	0.5	0.54	0.94	0.07	-0.12	0.74	0.02	0.71	0.86	0.32	-0.74	0.74		0.62	0.89	0.62	0.78	0.76	0.95	0.33	-0.48	0.95	0.28
Short Term Investments	0.4	0.04	0.44	0.35	0.39	0.79	0.36	0.06	0.42	-0.31	0.63	0.26	0.16	-0.41	0.57	0.62		0.43	0.43	0.38	0.78	0.77	0.17	-0.15	0.71	0.43
Capital Surpluse	0.45	-0.14	0.36	0.41	0.5	0.8	0.03	-0.17	0.61	0.04	0.6	0.82	0.25	-0.82	0.59	0.89	0.43		0.69	0.83	0.72	0.8	0.26	-0.59	0.82	0.18
Other Current Assets	0.05	0.13	0.57	0.0	0.22	0.64	0.36	-0.34	0.62	-0.31	0.3	0.59	-0.12	-0.34	0.39	0.62	0.43	0.69		0.56	0.73	0.67	-0.1	-0.11	0.7	-0.15
Other Stockholder Equity	0.23	0.17	0.5	0.18	0.15	0.71	0.26	-0.38	0.36	-0.2	0.57	0.68	-0.03	-0.62	0.26	0.78	0.38	0.83	0.56		0.72	0.7	-0.02	-0.53	0.7	0.06
Total Liab	0.32	0.39	0.82	0.26	0.32	0.82	0.34	-0.19	0.48	-0.28	0.58	0.55	0.08	-0.43	0.5	0.76	0.78	0.72	0.73	0.72		0.82	0.1	-0.15	0.79	0.24
Property Plant And Equipment Gross	0.44	-0.13	0.4	0.39	0.46	1.0	0.28	-0.18	0.74	-0.18	0.71	0.74	0.18	-0.7	0.71	0.95	0.77	0.8	0.67	0.7	0.82		0.19	-0.46	0.99	0.21
Total Current Assets	0.92	-0.26	-0.09	0.94	0.92	0.18	-0.85	0.83	0.29	0.89	0.45	0.42	1.0	-0.34	0.77	0.33	0.17	0.26	-0.1	-0.02	0.1	0.19		0.0	0.16	0.84
Common Stock	-0.16	0.47	0.21	-0.15	-0.15	-0.49	-0.11	0.24	-0.3	0.07	-0.37	-0.48	0.0	0.88	-0.22	-0.48	-0.15	-0.59	-0.11	-0.53	-0.15	-0.46	0.0		-0.49	0.12
Property Plant Equipment	0.39	-0.13	0.4	0.34	0.43	0.98	0.29	-0.24	0.79	-0.19	0.65	0.79	0.14	-0.7	0.69	0.95	0.71	0.82	0.7	0.7	0.79	0.99	0.16	-0.49		0.12
Other Assets	0.89	-0.12	0.01	0.89	0.8	0.24	-0.6	0.85	0.0	0.61	0.63	0.13	0.84	-0.23	0.61	0.28	0.43	0.18	-0.15	0.06	0.24	0.21	0.84	0.12	0.12

Click cells to compare fundamentals

Protara Therapeutics Account Relationship Matchups

Protara Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.0M	203.2M	172.6M	113.3M	79.0M	92.2M
Other Current Liab	320K	1.7M	1.6M	2.3M	1.7M	2.3M
Total Current Liabilities	583K	2.9M	4.3M	5.7M	6.1M	4.8M
Total Stockholder Equity	6.4M	199.2M	161.9M	102.1M	68.3M	85.5M
Net Tangible Assets	(12.1M)	169.7M	132.4M	102.1M	117.4M	71.9M
Property Plant And Equipment Net	459K	1.2M	8.9M	7.9M	6.6M	6.9M
Net Debt	(6.2M)	(167.5M)	(28.5M)	(17.7M)	(34.1M)	(35.8M)
Retained Earnings	(225.5M)	(46.8M)	(94.0M)	(160.0M)	(200.4M)	(210.4M)
Accounts Payable	263K	914K	954K	1.6M	2.4M	2.6M
Cash	6.2M	168.6M	35.7M	24.1M	39.6M	50.6M
Non Current Assets Total	581K	33.7M	79.5M	27.1M	10.2M	16.9M
Non Currrent Assets Other	122K	3.0M	1.6M	1.4M	3.7M	3.9M
Cash And Short Term Investments	6.2M	168.6M	91.2M	84.4M	65.6M	73.7M
Retained Earnings Total Equity	(189.7M)	(210.5M)	(225.5M)	(46.8M)	(42.1M)	(44.2M)
Common Stock Shares Outstanding	64.4K	7.2M	11.2M	11.3M	11.3M	11.9M
Liabilities And Stockholders Equity	7.0M	203.2M	172.6M	113.3M	79.0M	92.2M
Capital Surpluse	203.0M	209.4M	213.4M	246.0M	282.9M	228.9M
Other Current Assets	744K	837K	1.9M	1.3M	2.9M	1.6M
Other Stockholder Equity	213.4M	246.0M	256.1M	262.7M	268.7M	237.6M
Total Liab	583K	3.9M	10.7M	11.2M	10.6M	6.7M
Property Plant And Equipment Gross	0.0	1.2M	8.9M	7.9M	7.4M	7.8M
Total Current Assets	7.0M	169.4M	93.1M	86.1M	68.7M	75.4M
Accumulated Other Comprehensive Income	3K	0.0	(211K)	(688K)	(31K)	(32.6K)
Common Stock	18K	19K	3K	11K	9.9K	10.6K
Property Plant Equipment	459K	1.2M	8.9M	7.9M	9.0M	9.5M
Other Assets	(581K)	1.9M	1.6M	1.4M	1.0	0.95
Non Current Liabilities Total	263K	999K	6.4M	5.5M	4.5M	3.2M
Net Invested Capital	(12.1M)	199.2M	161.9M	102.1M	68.3M	95.0M
Net Working Capital	6.4M	166.5M	88.8M	80.4M	62.6M	77.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:

How To Invest In Protara

Details

Is Protara Stock a good investment?

Details

What is Protara Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.

You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.64)

Return On Assets

(0.28)

Return On Equity

(0.46)

The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protara Historical Balance Sheet

Protara Therapeutics Inventory

951,200

About Protara Balance Sheet Analysis

Protara Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Protara Therapeutics balance sheet Correlations

Protara Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protara Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant Equipment	+ 0.99	Property Plant And Equipment Gross
Property Plant Equipment	+ 0.98	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.95	Common Stock Shares Outstanding

Cash	- 0.99	Net Debt
Cash And Short Term Investments	- 0.86	Net Debt
Total Current Assets	- 0.85	Net Debt
Capital Surpluse	- 0.82	Common Stock Total Equity
Retained Earnings	- 0.79	Net Debt
Common Stock Shares Outstanding	- 0.74	Common Stock Total Equity